Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | AGXT | P21549 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248141 | 0.94 | IDO1 (0.54) | IDO1AGXTMAOBTAAR1CMA1 | |
| SCHEMBL21875857 | 0.86 | IDO1 (0.57) | IDO1AGXTMAOBTAAR1CMA1 | |
| SCHEMBL28443329 | 0.82 | IDO1 (0.53) | IDO1AGXTMAOBTAAR1CMA1 | |
| SCHEMBL29648388 | 0.81 | TSHR (0.51) | IDO1AGXTMAOBTAAR1MMP13 | |
| SCHEMBL16996790 | 0.81 | IDO1 (0.51) | IDO1AGXTMAOBMMP13HDAC1 | |
| SCHEMBL6828300 | 0.79 | CETP (0.59) | IDO1AGXT | |
| SCHEMBL31264 | 0.79 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CMA1 | |
| SCHEMBL3768643 | 0.79 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CMA1 | |
| SCHEMBL4801868 | 0.77 | IDO1 (0.50) | IDO1AGXTMAOBTAAR1CMA1 | |
| SCHEMBL6205291 | 0.76 | IDO1 (0.62) | IDO1AGXTMAOBTAAR1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | VIVAVISIONSHANGHAILTD (CN) | 2022-05-10 | — | — | US | disclosed |
| EP-3647315-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | Vivavisionshanghailtd (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200131206-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISIONSHANGHAILTD (CN) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | INPP5D, CXCL12, INPPL1 | IDO1 1533/4885AGXT 4375/4885MAOB 4184/4885 |
| US-20200131206-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | INPP5D, CXCL12, INPPL1 | IDO1 1533/4885AGXT 4375/4885MAOB 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.